0000000000280316

AUTHOR

Daniel Fuerst

showing 4 related works from this author

P043 HLA-DPB matching and donor cytomegalovirus positive (CMV+) status: An “unconventional alliance” associated with a decreased relapse incidence in…

2017

Aim While the role of HLA-DPB1 (DP) compatibility in uHSCT regarding graft versus host disease (GVHD)- and graft versus leukaemia (GVL)-effects has been extensively discussed, its interaction with donor CMV status (dCMV), remains elusive. The aim of this study was, to investigate the impact of dCMV status in DP matched (DPM) and mismatched (DPMM) uHSCT. Methods 1749 HSCT transplant (Tx) pairs were DP genotyped with an exon 2 amplicon based NGS approach in order to assess their DP matching status. CMV sero-status as well as clinical data were retrieved from the German Stem Cell Registry. Overall survival (OS), relapse incidence (RI) and chronic GvHD (cGvHD) were defined as endpoints, while s…

OncologyCMV statusmedicine.medical_specialtybusiness.industryIncidence (epidemiology)medicine.medical_treatmentImmunologyGeneral MedicineHuman leukocyte antigenHematopoietic stem cell transplantationmedicine.disease3. Good healthGraft-versus-host diseaseStatistical significanceInternal medicineImmunologyImmunology and AllergyMedicinebusinessCytomegalovirus PositiveCohort studyHuman Immunology
researchProduct

The Human Leukocyte Antigen-DPB1 Degree of Compatibility Is Determined by Its Expression Level and Mismatch Permissiveness: A German Multicenter Anal…

2021

T-cell epitope matching according to the TCE3 algorithm classifies HLA-DPB1 mismatches in permissive and non-permissive. This classification has been shown to be predictive for mortality and acute GvHD (aGvHD) events in large international cohorts. We retrospectively genotyped HLA-DPB1 in 3523 patients transplanted in Germany between 2000 and 2014 and in their unrelated donors using an Illumina amplicon-NGS based assay. Aim of the study was to evaluate DP-compatibility beyond the established TCE3 algorithm by assessing the combined effect of several DP-mismatch parameters on post-transplant outcome. We implemented an extended DP-mismatch assessment model where TCE3, DP allotype expression w…

MalePermissivenessOncologyGraft vs host diseaseEpitopes T-LymphocyteGraft vs Host DiseaseKaplan-Meier Estimategraft-versus-host-disease0302 clinical medicineGermanyImmunology and AllergyChild3' Untranslated RegionsHLA-DP beta-ChainsBone Marrow TransplantationOriginal Research0303 health sciencesHistocompatibility TestingIncidenceStem cell transplantationMiddle AgedAllograftsAllotype3. Good healthHLA-DPB1Child PreschoolHistocompatibility030220 oncology & carcinogenesisFemaleUnrelated Donorslcsh:Immunologic diseases. AllergyAdultRiskmedicine.medical_specialtyAdolescentImmunologyGraft vs Leukemia EffectHuman leukocyte antigenPolymorphism Single Nucleotidestem cell transplantationRelapse free survivalLymphocyte DepletionYoung Adult03 medical and health sciencesInternal medicinemedicineHumansTransplantat-Wirt-Reaktionddc:610PermissivePeriphere StammzellentransplantationAllelesAgedRetrospective Studies030304 developmental biologyPeripheral Blood Stem Cell TransplantationHLA-DPB1Donor selectionbusiness.industryInfant NewbornModels ImmunologicalInfantmedicine.diseaseGraft-versus-host diseaseHLA-DPB1-permissivenessHLA-DPB1 expressionlcsh:RC581-607businessFrontiers in Immunology
researchProduct

MICA-129 Dimorphism and Soluble MICA Are Associated With the Progression of Multiple Myeloma

2018

Natural killer (NK) cells are immune innate effectors playing a pivotal role in the immunosurveillance of multiple myeloma (MM) since they are able to directly recognize and kill MM cells. In this regard, among activating receptors expressed by NK cells, NKG2D represents an important receptor for the recognition of MM cells, being its ligands expressed by tumor cells, and being able to trigger NK cell cytotoxicity. The MHC class I-related molecule A (MICA) is one of the NKG2D ligands; it is encoded by highly polymorphic genes and exists as membrane-bound and soluble isoforms. Soluble MICA (sMICA) is overexpressed in the serum of MM patients, and its levels correlate with tumor progression. …

0301 basic medicineMaleModels MolecularProtein ConformationGenotypeImmunology and AllergyReceptorpredictive biomarkerOriginal ResearchAged 80 and overnatural killer cellsbiologyChemistryMiddle AgedImmunosurveillanceGene Expression Regulation NeoplasticKiller Cells Naturalmultiple myelomaNK Cell Lectin-Like Receptor Subfamily KDisease ProgressionFemaleNKG2D receptorProtein Bindinglcsh:Immunologic diseases. AllergyGenotypeImmunologyEnzyme-Linked Immunosorbent AssayMICA polymorphismImmunophenotyping03 medical and health sciencesStructure-Activity RelationshipImmune systemMHC class IHumansGenetic Predisposition to DiseaseAllelesGenetic Association StudiesAgedPolymorphism GeneticHistocompatibility Antigens Class INKG2DMolecular biologyMolecular Typingstomatognathic diseases030104 developmental biologyAmino Acid SubstitutionTumor progressionbiology.proteinmultiple myeloma natural killer cells NKG2D receptor MICA polymorphism predictive biomarkerGene polymorphismlcsh:RC581-607Frontiers in Immunology
researchProduct

Matching for the MICA-129 polymorphism is beneficial in unrelated hematopoietic stem cell transplantation.

2016

Major histocompatibility complex class I polypeptide-related sequence A (MICA) is a highly polymorphic ligand of the activating NKG2D receptor on natural killer (NK) cells, γδ-T cells, and NKT cells. MICA incompatibilities have been associated with an increased graft-versus-host disease (GVHD) incidence, and the MICA-129 (met/val) dimorphism has been shown to influence NKG2D signaling in unrelated hematopoietic stem cell transplantation (uHSCT). We investigated the effect of MICA matching on survival after uHSCT. We sequenced 2172 patients and their respective donors for MICA. All patients and donors were high-resolution HLA-typed and matched for 10/10 (n = 1379), 9/10 (n = 636), or 8/10 (n…

0301 basic medicineAdultMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentImmunologyHematopoietic stem cell transplantationHuman leukocyte antigenMajor histocompatibility complexBiochemistryGastroenterology03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicinemedicineMinor histocompatibility antigenHumansAgedPolymorphism GeneticbiologyDonor selectionbusiness.industryHistocompatibility TestingHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationCell BiologyHematologyMiddle AgedNKG2DNatural killer T cellSurvival AnalysisTissue DonorsSurgeryTransplantationstomatognathic diseases030104 developmental biologyGenetic LociMultivariate Analysisbiology.proteinFemalebusiness030215 immunologyBlood
researchProduct